Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.

Annals of hematology - 1 Nov 2018

Wang Hong, Li Yan, Lv Na, Li Yonghui, Wang Lili, Yu Li

Abstract excerpt

Azacitidine and decitabine, two hypomethylating agents, are known to be effective in the treatment of high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) patients who cannot endure intensive cytotoxic chemotherapy or are not eligible for transplantation. However, the treatment response rate is low. The molecular mechanisms underlying the resistance to demethylation therapy are unclear....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to DNA Methylation
Share to DNA, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Leukemic

Share to Leukemia, Myeloid, Acute

Share to Myelodysplastic Syndromes

Share to Neoplasm Proteins

Share to Predictive Value of Tests

Source

Identifiers

PMID: 30084010
DOI: 10.1007/s00277-018-3464-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes.PMID 30084010Read ↗

Predicting outcome in higher-risk myelodysplastic syndrome patients treated with azacitidine.Semantic proximity Read ↗

Targeting DNA Methylation in Leukemia, Myelodysplastic Syndrome, and Lymphoma: A Potential Diagnostic, Prognostic, and Therapeutic ToolSemantic proximity Read ↗

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.Semantic proximity Read ↗

Why methylation is not a marker predictive of response to hypomethylating agents.Semantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective studySemantic proximity Read ↗

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic SyndromeSemantic proximity Read ↗

Unique epigenomic signatures identify biologically significant subtypes of MDS and predict response to azacitidineSemantic proximity Read ↗

Advances in the management of higher-risk myelodysplastic syndromes: future prospects.Semantic proximity Read ↗

An update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSemantic proximity Read ↗

A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersSemantic proximity Read ↗

DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.